James Dentzer News Today

LEXINGTON, Mass., April 4, 2024 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James...

(RTTNews) - Curis, Inc. (CRIS), Tuesday said it has reached a clinical trial agreement with the University of Florida to study the combination of ...

LEXINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment...

Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance...

A partial clinical trial hold has been lifted from cancer drug emavusertib and Curis has selected a dose to use in Phase 2 testing. The small molecule is being developed as a potential treatment for blood cancers.

LEXINGTON - Curis, Inc., , a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor for the treatment of hematologic...

/PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple...

The FDA has lifted a partial clinical hold on the phase 1/2 TakeAim Leukemia trial evaluating emavusertib monotherapy and in combination with azacitidine and venetoclax in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Operator: Good morning, and welcome to the Curis Fourth Quarter 2022 Business Update Call. Please note, this event is being recorded.